Palbociclib and Trastuzumab combination

The combination of palbociclib and trastuzumab is a therapeutic regimen used primarily for treating HER2-positive, hormone receptor-positive (HR+/HER2+) breast cancer. This combination represents a chemo-free treatment approach that targets multiple pathways involved in cancer cell growth. Palbociclib is a cyclin-dependent kinase (CDK4/6) inhibitor that blocks cell cycle progression, while trastuzumab is a monoclonal antibody that targets the HER2 protein. When used together, they provide complementary mechanisms of action that can effectively control cancer growth, particularly in patients with HR+/HER2+ breast cancer.